Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

被引:51
作者
Zannad, F
Gille, B
Grentzinger, A
Bruntz, JF
Hammadi, M
Boivin, JM
Hanotin, C
Igau, B
Drouin, P
机构
[1] CHU Nancy, Hop Jeanne Arc, INSERM, Ctr Invest Clin, Toul, France
[2] CHU Nancy, Hop Jeanne Arc, Serv Diabetol Malad Metab & Nutr, Toul, France
[3] Hop Brabois, Serv Cardiol, Nancy, France
[4] Hop Cent, Serv Cardiol, Nancy, France
[5] Labs Knoll France, Div Therapeut Metab, Levallois Perret, France
关键词
D O I
10.1067/mhj.2002.124403
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Obesity enhances hemodynamic alterations that predispose to a subsequent increase in left ventricular (LV) wall stress leading to LV hypertrophy. In obese subjects, weight reduction regresses LV mass (LVM), regardless of blood pressure. Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss. Methods Outpatients (n = 184, age 18-65 y, body mass index greater than or equal to30 to <40 kg/m(2)) were randomly assigned to 6 months of once daily double-blind treatment with sibutramine 10 mg or 20 mg, or placebo. IV dimensions, status and function of the valves, weight loss, blood pressure, heart rate, and electrocardiogram were assessed. Results For end point data sets, the mean 51) LVM index (LVM/height) changes were -3.0 +/- 11.9 g/m for placebo (n = 56), -4.4 +/- 10.7 g/m for sibutramine 10 mg (n = 6 1), and -4.3 +/- 10.9 g/m for sibutramine 20 mg (n 56). The reductions observed in the sibutramine groups were statistically significant compared with baseline (P < .01), but pairwise comparison results with placebo were not statistically significant. There was no difference in overall status of the cardiac valves. A statistically significant greater weight loss was found in patients on both doses of sibutramine compared with placebo (P < .001). No statistically significant differences between the groups were observed in respect to blood pressure and electrocardiographic intervals, but a statistically significant increase in pulse rate (7 beats/min) was noted for patients with sibutramine treatment. Conclusion A 6-month treatment with sibutramine does not affect ventricular dimensions, heart valves, and electrocardiogram variables.
引用
收藏
页码:508 / 515
页数:8
相关论文
共 39 条
[1]   THE CARDIOMYOPATHY OF OBESITY [J].
ALEXANDER, JK .
PROGRESS IN CARDIOVASCULAR DISEASES, 1985, 27 (05) :325-334
[2]  
ALEXANDER JK, 1963, CARDIOVASC RES CENT, V7, P39
[3]   EFFECT OF WEIGHT-LOSS ON LEFT-VENTRICULAR MASS IN NONHYPERTENSIVE MORBIDLY OBESE PATIENTS [J].
ALPERT, MA ;
LAMBERT, CR ;
TERRY, BE ;
KELLY, DL ;
PANAYIOTOU, H ;
MUKERJI, V ;
MASSEY, CV ;
COHEN, MV .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (12) :918-921
[4]   OBESITY AND THE HEART [J].
ALPERT, MA ;
HASHIMI, MW .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1993, 306 (02) :117-123
[5]  
ARMITAGE P, 1987, STAT METHODS MED RES, P106
[6]   Absence of cardiac valve dysfunction in obese patients treated with sibutramine [J].
Bach, DS ;
Rissanen, AM ;
Mendel, CM ;
Shepherd, G ;
Weinstein, SP ;
Kelly, F ;
Seaton, TB ;
Patel, B ;
Pekkarinen, TA ;
Armstrong, WF .
OBESITY RESEARCH, 1999, 7 (04) :363-369
[7]   Sibutramine produces dose-related weight loss [J].
Bray, GA ;
Blackburn, GL ;
Ferguson, JM ;
Greenway, FL ;
Jain, AK ;
Mendel, CM ;
Mendels, J ;
Ryan, DH ;
Schwartz, SL ;
Scheinbaum, ML ;
Seaton, TB .
OBESITY RESEARCH, 1999, 7 (02) :189-198
[8]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588
[9]   RELATION OF OBESITY AND GENDER TO LEFT-VENTRICULAR HYPERTROPHY IN NORMOTENSIVE AND HYPERTENSIVE ADULTS [J].
DESIMONE, G ;
DEVEREUX, RB ;
ROMAN, MJ ;
ALDERMAN, MH ;
LARAGH, JH .
HYPERTENSION, 1994, 23 (05) :600-606
[10]   ECHOCARDIOGRAPHIC DETERMINATION OF LEFT-VENTRICULAR MASS IN MAN - ANATOMIC VALIDATION OF METHOD [J].
DEVEREUX, RB ;
REICHEK, N .
CIRCULATION, 1977, 55 (04) :613-618